• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ZeroStack Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/20/26 4:02:11 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZSTK alert in real time by email
    ZeroStack Corp.: Form 8-K - Filed by newsfilecorp.com

    false 2026-07-20 0001790169 --12-31 00-0000000 ZeroStack Corp. 0001790169 2026-07-20 2026-07-20

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 20, 2026

    ZEROSTACK CORP.
    (Exact name of registrant as specified in its charter)

    Ontario 001-40397 Not Applicable
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    2626 Cole Ave, Suite 300
    Dallas, Texas, United States 75204
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (954) 842-4989

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on
    which registered
    Common Shares, no par value   ZSTK   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    ZeroStack Corp., a corporation organized under the laws of the Province of Ontario (the "Company") held its 2026 Annual and Special Meeting of Shareholders (the "Meeting") on July 20, 2026.

    The 2022 Plan Amendment

    At the Meeting, the Company's shareholders approved an amendment (the "2022 Plan Amendment") of the Company's 2022 Incentive Compensation Plan, as amended on June 6, 2023, August 14, 2024, June 30, 2025 and December 19, 2025 (the "2022 Plan") to (i) increase the number of common shares of the Company (the "Common Shares") issuable thereunder from 1,506,892 to 3,006,892, (ii) increase the number of Incentive Stock Options (as defined in the 2022 Plan) issuable thereunder from 847,843 to 1,695,686 and (iii) update all mentions of "Flora Growth Corp." to "ZeroStack Corp."

    The 2022 Plan Amendment became effective immediately upon shareholder approval at the Meeting. A more complete summary of the terms of the 2022 Plan Amendment is set forth in "Proposal 4: Approval of the 2022 Plan Amendment Proposal" in the Company's proxy statement/prospectus filed with the Securities and Exchange Commission on June 17, 2026 (the "Proxy Statement/Prospectus"), which description and text are incorporated herein by reference.

    The foregoing description of the terms of the 2022 Plan Amendment and the description thereof incorporated by reference from the Proxy Statement/Prospectus do not purport to be complete and are qualified in their entirety by reference to the full text of the 2022 Plan, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Stock Option Grants to CEO, CFO and Executive Chairman 

    At the Meeting, the Company's shareholders approved the grant of stock options to the Company's Chief Executive Officer, Chief Financial Officer and Executive Chairman as detailed in the Company's Current Report on Form 8-K filed on May 6, 2026 and as set forth in "Proposal No. 5: Approval of the Stock Options Proposal" in the Company's Proxy Statement/Prospectus, which description and text are incorporated by reference herein. 

    Item 5.03 Amendments to the Articles of Incorporation or Bylaws, Change in Fiscal Year.

    At the Meeting, the Company's shareholders approved the ratification of an amendment to the Bylaws of the Company (the "Bylaws") to divide the directors of the Company's board of directors (the "Board") into three classes, with directors in each class to serve staggered terms of one to three years, as described in more detail in the Proxy Statement/Prospectus as set forth in "Proposal No. 5: Approval of the Stock Options Proposal" in the Company's Proxy Statement/Prospectus, which description and text are incorporated by reference herein (the "Bylaws Amendment").

    The foregoing description of the terms of the Bylaws Amendment and the description thereof incorporated by reference from the Proxy Statement/Prospectus do not purport to be complete and are qualified in their entirety by reference to the full text of the amended Bylaws, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    The final voting results for the proposals submitted to a vote of the Company's shareholders at the Meeting are as follows:

    Proposal 1: Election of five directors to the Board to hold office until the Company's 2027 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified. If Proposal 7 is approved, the Board will be staggered as described in the Proxy Statement/Prospectus. 

                    Broker
    Director   For   Against   Abstentions   Non-Votes
    Daniel Reis-Faria   1,014,396   233,594   381   263,006
    Michael Heinrich   1,016,473   231,525   373   263,006
    Edward Woo   1,012,715   233,242   2,414   263,006
    Manfred Leventhal   1,012,441   233,518   2,412   263,006
    Laurence Zeifman   1,013,329   232,635   2,407   263,006

    Proposal 2: Reappointment of Davidson & Company LLP, an independent registered public accounting firm, as auditors of the Company for the fiscal year ending December 31, 2026 and authorization of the Board to fix their renumeration. 

    For

     

    Against

     

    Abstentions

    1,240,565

     

    1,510

     

    269,302

    Proposal 3: Approval, for purposes of complying with Nasdaq Listing Rules 5635(a), 5635(c) and 5635(d), of the issuance of 9,104,614 Common Shares to be exchanged for 9,104,614 shares of Texas Blocker Corp. in the Company's private placement transactions entered into by the Company with certain investors, pursuant to the share exchange agreement dated March 31, 2026. 

     

     

     

     

     

     

    Broker

    For

     

    Against

     

    Abstentions

     

    Non-Votes

    1,194,800

     

    51,630

     

    1,941

     

    263,006

    Proposal 4: Approval of the 2022 Plan Amendment to the 2022 Plan, to (i) increase the number of Common Shares issuable thereunder from 1,506,892 to 3,006,892, (ii) increase the number of Incentive Stock Options issuable thereunder from 847,843 to 1,695,686 and (iii) update all mentions of "Flora Growth Corp." to "ZeroStack Corp."

     

     

     

     

     

     

    Broker

    For

     

    Against

     

    Abstentions

     

    Non-Votes

    658,518

     

    588,898

     

    955

     

    263,006



    Proposal 5: Approval of the grant of stock options to the Company's Chief Executive Officer, Chief Financial Officer, and Executive Chairman.

     

     

     

     

     

     

    Broker

    For

     

    Against

     

    Abstentions

     

    Non-Votes

    688,581

     

    555,566

     

    4,224

     

    263,006

    Proposal 6: Give the Board authority, at its discretion, to change the jurisdiction of incorporation of the Company from the Province of Ontario to the State of Texas.

     

     

     

     

     

     

    Broker

    For

     

    Against

     

    Abstentions

     

    Non-Votes

    1,002,488

     

    245,106

     

    777

     

    263,006


    Proposal 7: Approval of the ratification of an amendment to the bylaws of the Company to divide the directors of the Board into three classes, each serving staggered terms of one to three years, as described in the Proxy Statement/Prospectus. 

     

     

     

     

     

     

    Broker

    For

     

    Against

     

    Abstentions

     

    Non-Votes

    652,309

     

    595,221

     

    841

     

    263,006

    Proposal 8: Approval of one or more adjournments or postponements of the Meeting by the Company from time to time to permit further solicitation of proxies, if necessary or appropriate, if sufficient votes are not represented at the Meeting to approve one or more of Proposals Nos. 1-7 at the time of such adjournment or postponement or if otherwise determined by the chairperson of the Meeting to be necessary or appropriate. 

             
    For   Against   Abstentions
    853,255   654,074   4,048

    Based on the foregoing votes, Proposals 1, 2, 3, 4, 5, 6, 7 and 8 were approved. No other proposals were submitted for shareholder approval at the Meeting.

    Since Proposal 7 was approved and the shareholders ratified the amendment to the Bylaws to provide for a staggered Board, set forth below is information regarding the director classes to which the foregoing nominees were elected. 

    Class I
    (initial term expiring at the 2027 Annual Meeting of Shareholders)

    Class II
    (initial term expiring at the 2028 Annual Meeting of Shareholders)

    Class III
    (initial term expiring at the 2029 Annual Meeting of Shareholders)
    Michael Heinrich   Daniel Reis-Faria   Edward Woo
    Manfred Leventhal   Laurence Zeifman    


    Item 9.01 Financial Statements and Exhibits.

    Exhibit No. Description
    3.1 Bylaw No. 1-A of Zero Stack Corp., as amended July 20, 2026 
    4.1 2022 Incentive Compensation Plan, as amended on June 6, 2023, August 14, 2024, June 30, 2025, December 19, 2025 and July 20, 2026
    104 Cover Page Interactive Data File

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

      FLORA GROWTH CORP.
         
    Date: July 20, 2026 By: /s/ Dany Vaiman
      Name: Dany Vaiman
      Title: Chief Financial Officer


    Get the next $ZSTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZSTK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZSTK
    SEC Filings

    View All

    ZeroStack Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ZeroStack Corp. (0001790169) (Filer)

    7/20/26 4:02:11 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ZeroStack Corp.

    EFFECT - ZeroStack Corp. (0001790169) (Filer)

    6/18/26 12:15:34 AM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by ZeroStack Corp.

    424B3 - ZeroStack Corp. (0001790169) (Filer)

    6/17/26 4:53:30 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Heinrich Michael bought $3,479,013 worth of shares (4,608,575 units at $0.75) (SEC Form 4)

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:31:03 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Reis-Faria Daniel exercised 5,954,743 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:26:15 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CFO Vaiman Dany

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:21:25 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZeroStack Announces Results of 2026 Annual and Special Meeting of Shareholders, Provides Phatebo Purchase Orders Update and Announces Closing of Previously Announced Cryptocurrency Financing

    Dallas, Texas--(Newsfile Corp. - July 20, 2026) - ZeroStack Corp. (NASDAQ:ZSTK) ("ZeroStack" or the "Company"), the first Nasdaq-listed, AI-focused asset management company, held its 2026 Annual and Special Meeting of Shareholders (the "Meeting"). The final voting results of the proposals submitted to a vote of the Company's shareholders at the Meeting are as follows: Proposal 1: Election of five directors to the board of directors of the Company (the "Board") to hold office until the Company's 2027 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified. If Proposal 7 is approved, the Board will be staggered as described in the proxy statement/pros

    7/20/26 4:01:00 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companies

    Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - ZeroStack Corp. (NASDAQ:ZSTK) (the "Company" or "ZeroStack"), the first Nasdaq-listed, AI-focused asset management company, today announced that it has secured pharmaceutical distribution purchase orders for up to approximately US$14.7 million (EUR 12.9 million) of inventory in Germany from two companies (the "Orders"). The Orders are expected to be fulfilled through the Company's wholly owned German subsidiary, Phatebo GmbH ("Phatebo").Phatebo has operated as a pharmaceutical distributor in Europe for more than then years and serves as the Company's primary operating subsidiary. In connection with ZeroStack's long-term strategy, Phatebo co

    7/9/26 8:01:00 AM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DeFi Dev Corp. Announces Strategic Leadership Transition of DisclaimerCoin (DONT) to Dedicated Ecosystem Team

    BOCA RATON, FL, July 08, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (NASDAQ:DFDV) (the "Company"), the first U.S. public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced the strategic transition of leadership for DisclaimerCoin ("DONT"), the world’s first publicly traded company-created memecoin, to Daniel Reis-Faria, Chief Executive Officer of Nasdaq-listed ZeroStack Holdings Inc. (NASDAQ:ZSTK), and a dedicated team focused exclusively on growing the DisclaimerCoin ecosystem. The transition represents the next phase in DisclaimerCoin’s evolution. While DFDV pioneered the historic launch of DONT in January 2026, the Company believes th

    7/8/26 9:00:00 AM ET
    $DFDV
    $ZSTK
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Heinrich Michael bought $3,479,013 worth of shares (4,608,575 units at $0.75) (SEC Form 4)

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:31:03 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Leadership Updates

    Live Leadership Updates

    View All

    DeFi Dev Corp. Announces Strategic Leadership Transition of DisclaimerCoin (DONT) to Dedicated Ecosystem Team

    BOCA RATON, FL, July 08, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (NASDAQ:DFDV) (the "Company"), the first U.S. public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced the strategic transition of leadership for DisclaimerCoin ("DONT"), the world’s first publicly traded company-created memecoin, to Daniel Reis-Faria, Chief Executive Officer of Nasdaq-listed ZeroStack Holdings Inc. (NASDAQ:ZSTK), and a dedicated team focused exclusively on growing the DisclaimerCoin ecosystem. The transition represents the next phase in DisclaimerCoin’s evolution. While DFDV pioneered the historic launch of DONT in January 2026, the Company believes th

    7/8/26 9:00:00 AM ET
    $DFDV
    $ZSTK
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care